In a report published Friday, Canaccord Genuity reiterated its Buy rating on Hi-Tech Pharmacal Co. HITK, but lowered its price target from $42.00 to $40.00.
Canaccord Genuity noted, “HITK reported F3Q results that brought some cough-and-cold-driven revenue upside that was appropriately overshadowed by the cost-driven EPS miss. While the spend surprise was disappointing, the operational results were overall decent. Post F3Q, we have a hard time from here pointing to near-term drivers that can push the stock higher absent a deal. That said, we see a lot of potential in the platform on a combination of three things: (1) a higher barrier base business; (2) a pipeline we think can bring solid medium term P&L support; and (3) financial flexibility that can and should be used to pursue a sizable deal, which we think would bring welcome diversification from fluticasone.”
Hi-Tech Pharmacal Co. closed on Thursday at $36.16.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in